- Ribavirin
- Palivizumab
- Nirsevimab
- JNJ 53718678
- Enanta EDP-938
- ASCENIV
- Others
Respiratory Syncytial Virus Therapeutics Market was valued at USD 2,673.9 million in 2023 and is expected to grow at a 12.1% CAGR from 2024 to 2030. Respiratory Syncytial Virus (RSV) is a common respiratory pathogen that causes significant morbidity and mortality, particularly in infants, young children, and older adults. The global respiratory syncytial virus therapeutics market is experiencing substantial growth driven by increasing awareness of respiratory syncytial virus's impact, rising incidence rates, and advancements in treatment options. The respiratory syncytial virus therapeutics market is primarily fueled by the development of novel therapies, expanding vaccination programs, and growing healthcare expenditure worldwide. Recent outbreaks and the COVID-19 pandemic have heightened awareness about respiratory infections, further propelling respiratory syncytial virus therapeutics market growth.
The market is witnessing a shift towards the development of long-acting monoclonal antibodies and small-molecule antivirals, offering improved efficacy and convenience. Moreover, strategic collaborations between pharmaceutical companies and research institutions are playing a crucial role in market expansion, accelerating the development of innovative therapies. The growing demand for preventive measures, particularly in high-risk populations such as premature infants and the elderly, is reshaping the market landscape. Additionally, the potential approval of respiratory syncytial virus vaccines for different age groups could significantly impact the market dynamics.
However, the respiratory syncytial virus therapeutics market faces challenges such as the high cost of immunoprophylaxis drugs and the seasonal nature of respiratory syncytial virus infections, which may impact consistent revenue generation. Despite these challenges, the market is expected to continue its upward trajectory, driven by the unmet medical need in respiratory syncytial virus treatment and the expanding scope of research in this area. Moreover, government agencies and healthcare organizations worldwide have been actively investing in respiratory syncytial virus research and preparedness. For instance, the National Institute of Allergy and Infectious Diseases (NIAID) has allocated substantial funding for respiratory syncytial virus vaccine development and therapeutics research. In 2022, the NIAID announced a $577 million investment in respiratory syncytial virus research, highlighting the growing focus on combating this virus.
Respiratory Syncytial Virus (RSV) Therapeutics Market Key Developments:
- In May 2023, GlaxoSmithKline plc announced that the USFDA had approved its respiratory syncytial virus vaccine called Arexvy to do away with lower respiratory tract disease contracted from respiratory syncytial virus infection in those aged 60 and above
- In November 2022, Pfizer Inc. announced that the USFDA had accepted its respiratory vaccine candidate PF-06928316/respiratory syncytial viruspreF.
Respiratory Syncytial Virus (RSV) Therapeutics Market Summary
Study Period
2024-2030Base Year
2023CAGR
12.1%Largest Market
North-AmericaFastest Growing Market
North-AmericaRespiratory Syncytial Virus Therapeutics Market Dynamics
The respiratory syncytial virus therapeutics market is primarily driven by the high burden of respiratory syncytial virus infections, particularly in vulnerable populations. The World Health Organization estimates that respiratory syncytial virus causes about 33 million lower respiratory tract infections globally each year in children under 5, resulting in more than 3 million hospitalizations and up to 120,000 deaths. This significant disease burden has led to increased research and development efforts. Another key driver is the growing awareness among healthcare providers and the general public about the potential severity of respiratory syncytial virus infections. This has resulted in earlier diagnosis and treatment, expanding the patient pool for respiratory syncytial virus therapeutics. The expansion of immunization programs in both developed and developing countries is also contributing to market growth. The potential introduction of maternal respiratory syncytial virus vaccines could significantly impact the market by reducing the incidence of severe respiratory syncytial virus in infants. Additionally, the development of combination therapies targeting multiple respiratory viruses presents new opportunities for market players. The COVID-19 pandemic has also heightened awareness about respiratory infections, leading to increased funding and research in this area.
North-America Got Significant Share of
Respiratory Syncytial Virus Therapeutics Market Regional Analysis
North America respiratory syncytial virus therapeutics market is expected to dominate due to high healthcare expenditure, advanced medical infrastructure, and the presence of key market players. The U.S. leads the North American market in terms of revenue. Moreover, the Asia Pacific respiratory syncytial virus therapeutics market is expected to grow at the highest CAGR among all regions. This rapid growth can be attributed to improving healthcare infrastructure, rising awareness about respiratory syncytial virus, and increasing government initiatives for reducing infant mortality rates. Countries like China and India are investing in improving their healthcare systems, further driving regional market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
Respiratory Syncytial Virus (RSV) Therapeutics Market Segmentation
By Molecule
By Dosage Form
- Oral
- Injectable
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Frequently Asked Questions
The respiratory syncytial virus therapeutics market was valued at USD 2,673.9 million in 2023 and is expected to grow at a 12.1% CAGR from 2024 to 2030.
AstraZeneca plc, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., and Sanofi S.A. are some of the major players operating in the respiratory syncytial virus therapeutics market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the respiratory syncytial virus therapeutics market.
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global Respiratory Syncytial Virus Therapeutics Market Introduction |
| 2.1.Global Respiratory Syncytial Virus Therapeutics Market - Taxonomy |
| 2.2.Global Respiratory Syncytial Virus Therapeutics Market - Definitions |
| 2.2.1.Molecule |
| 2.2.2.Dosage Form |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Respiratory Syncytial Virus Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Respiratory Syncytial Virus Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Respiratory Syncytial Virus Therapeutics Market By Molecule, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Ribavirin |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Palivizumab |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Nirsevimab |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. JNJ 53718678 |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Enanta EDP-938 |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. ASCENIV |
| 5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Others |
| 5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 6.Global Respiratory Syncytial Virus Therapeutics Market By Dosage Form, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Injectable |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Respiratory Syncytial Virus Therapeutics Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacy |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacy |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacy |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Respiratory Syncytial Virus Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Respiratory Syncytial Virus Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Molecule Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Ribavirin |
| 9.1.2.Palivizumab |
| 9.1.3.Nirsevimab |
| 9.1.4.JNJ 53718678 |
| 9.1.5.Enanta EDP-938 |
| 9.1.6.ASCENIV |
| 9.1.7.Others |
| 9.2. Dosage Form Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Injectable |
| 9.2.3.Others |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacy |
| 9.3.2.Retail Pharmacy |
| 9.3.3.Online Pharmacy |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Respiratory Syncytial Virus Therapeutics Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Ribavirin |
| 10.1.2.Palivizumab |
| 10.1.3.Nirsevimab |
| 10.1.4.JNJ 53718678 |
| 10.1.5.Enanta EDP-938 |
| 10.1.6.ASCENIV |
| 10.1.7.Others |
| 10.2. Dosage Form Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Injectable |
| 10.2.3.Others |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacy |
| 10.3.2.Retail Pharmacy |
| 10.3.3.Online Pharmacy |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Respiratory Syncytial Virus Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Ribavirin |
| 11.1.2.Palivizumab |
| 11.1.3.Nirsevimab |
| 11.1.4.JNJ 53718678 |
| 11.1.5.Enanta EDP-938 |
| 11.1.6.ASCENIV |
| 11.1.7.Others |
| 11.2. Dosage Form Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Injectable |
| 11.2.3.Others |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacy |
| 11.3.2.Retail Pharmacy |
| 11.3.3.Online Pharmacy |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Respiratory Syncytial Virus Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Ribavirin |
| 12.1.2.Palivizumab |
| 12.1.3.Nirsevimab |
| 12.1.4.JNJ 53718678 |
| 12.1.5.Enanta EDP-938 |
| 12.1.6.ASCENIV |
| 12.1.7.Others |
| 12.2. Dosage Form Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Injectable |
| 12.2.3.Others |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacy |
| 12.3.2.Retail Pharmacy |
| 12.3.3.Online Pharmacy |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Respiratory Syncytial Virus Therapeutics Market 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Molecule Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Ribavirin |
| 13.1.2.Palivizumab |
| 13.1.3.Nirsevimab |
| 13.1.4.JNJ 53718678 |
| 13.1.5.Enanta EDP-938 |
| 13.1.6.ASCENIV |
| 13.1.7.Others |
| 13.2. Dosage Form Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Injectable |
| 13.2.3.Others |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacy |
| 13.3.2.Retail Pharmacy |
| 13.3.3.Online Pharmacy |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Merck & Co., Inc. |
| 14.2.2.Pfizer Inc. |
| 14.2.3.Sanofi S.A. |
| 14.2.4.Novavax, Inc. |
| 14.2.5.ReViral Ltd. |
| 14.2.6.Celltrion Inc. |
| 14.2.7.GlaxoSmithKline plc |
| 14.2.8.AbbVie, Inc. |
| 14.2.9.Hoffmann-La Roche Ltd. |
| 14.2.10.Gilead Sciences, Inc. |
| 14.2.11.Teva Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- AstraZeneca plc
- GlaxoSmithKline plc
- AbbVie, Inc.
- Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Sanofi S.A.
- Novavax, Inc.
- ReViral Ltd.
- Celltrion Inc.